Search filters

List of works by Kami Maddocks

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

scientific article

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

scientific article published on 13 February 2017

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy

scientific article published on 27 July 2017

Chemotherapy-free induction in MCL: ready for prime time?

scientific article published on 01 November 2018

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

scientific article

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

scientific article published on 23 November 2016

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

scientific article published on 02 October 2018

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

scientific article published in April 2015

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

scientific article published on 22 July 2015

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

scientific article published on 25 July 2013

Ibrutinib treatment improves T cell number and function in CLL patients

scientific article published on 17 July 2017

Jumping translocations, a novel finding in chronic lymphocytic leukaemia

scientific article published on 19 April 2015

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

scientific article published on 15 August 2018

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

scientific article published on 08 June 2020

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

scientific article published on 10 January 2014

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

scientific article

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

scientific article

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

scientific article published on 07 January 2019

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

scientific article

Update on Mantle Cell Lymphoma

scientific article published on 28 August 2018

Paulina is supported by:

About Paulina

Help